AXL and cancer: For example, the potential to restore immunotherapeutic sensitivity to STK11-driven cancers by inhibiting CoREST deacetylase activity has been explored via Tango Therapeutics’ compound TNG26060, or via inhibitors of AXL, CDK4/6, or STAT361–63.